Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PURE BIOSCIENCE, INC.PURE · Entity 7969 | Director | February 26, 2018 | March 01, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PURE BIOSCIENCE, INC.
Report date February 26, 2018 · Filed March 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2023-02-27 | Direct | 100,000 |
Reported balance
After 2018-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-26 · Grant · Acquired 100,000 · Balance 100,000 F1: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2019 or January 15, 2019 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2020 or January 15, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2019 or January 15, 2019 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2020 or January 15, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2018 Filed Mar 1, 2018 00:15 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-18-014693 · doc4.xml · derivative · entry 1 Hagen Elisabeth · CIK 0001721211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2023-02-27 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2019 or January 15, 2019 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2020 or January 15, 2020. Read SEC document |
| November 02, 2017 Filed Nov 3, 2017 21:12 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-17-059249 · doc4.xml · derivative · entry 2 Hagen Elisabeth · CIK 0001721211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-11-02 F2 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2018 or January 15, 2018 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2019 or January 15, 2019. Read SEC document |
| November 02, 2017 Filed Nov 3, 2017 21:12 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-059249 · doc4.xml · nonDerivative · entry 1 Hagen Elisabeth · CIK 0001721211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F1 · shares: Represents the issuance of restricted stock units (the "RSUs"). The RSUs vest and become exercisable as follows: (i) 50% of the RSUs will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2018 or January 15, 2018 and (ii) 50% of the RSUs will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2019 or January 15, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.